Mexico Cough Hypersensitivity Syndrome Therapeutics Market Report 2022 to 2030

Mexico Cough Hypersensitivity Syndrome Therapeutics Market Analysis

$ 3999

The Mexico Cough Hypersensitivity Syndrome Therapeutics Market was valued at $122 Mn in 2022 and is predicted to grow at a CAGR of 6.15% from 2023 to 2030, to $196 Mn by 2030. The main factors driving this industry include the increasing prevalence of Cough Hypersensitivity Syndrome, expanding healthcare infrastructure, and the development of advanced therapeutics. The industry is primarily dominated by players such as Roche, Pfizer, Teva, Novartis, Johnson & Johnson, and GSK among others.

CATEGORY: Pharmaceuticals GEOGRAPHY: Mexico AUTHOR: Riddhi Solanki

Buy Now

Mexico Cough Hypersensitivity Syndrome Therapeutics Market Analysis Executive Summary

The Mexico Cough Hypersensitivity Syndrome Therapeutics Market is at around $122 Mn in 2022 and is projected to reach $196 Mn in 2030, exhibiting a CAGR of 6.15% during the forecast period.

An enhanced coughing reflex in reaction to stimuli such as temperature changes, mechanical causes, or chemical exposure characterizes Cough Hypersensitivity Syndrome (CHS). CHS is related to pre-existing diseases such as asthma, upper airway cough syndrome (UACS), gastroesophageal reflux disease (GERD), rhinitis, chronic obstructive pulmonary disease (COPD), and pulmonary fibrosis. CHS risk factors include higher sensitivity to cough-inducing stimuli such as citric acid and capsaicin. Treatment options include antitussive medicines, inhaled corticosteroids, anticholinergics, antihistamines, and neurokinin-1 receptor antagonists among others. Leading pharmaceutical companies like Johnson & Johnson, Bayer AG, Teva, GlaxoSmithKline plc, Pfizer, Novartis, and AstraZeneca manufacture CHS drugs.

Mexico faces a significant burden of chronic cough which has an estimated prevalence of around 3%-8% in the population. Several factors contribute to market growth including the rising prevalence of Cough Hypersensitivity Syndrome and subsequently its risk factors like smoking and pollution, expanding healthcare infrastructure, and the development of advanced therapeutics. However, conditions such as affordability challenges, limited efficacy of existing treatments, and a fragmented healthcare system restrict the growth and potential of the market.

Market Dynamics

Market Growth Drivers

Increasing prevalence of Cough Hypersensitivity Syndrome: Mexico faces a substantial burden of chronic respiratory conditions such as asthma, COPD, and allergic rhinitis, all of which may contribute to the prevalence of CHS. Chronic cough has an estimated prevalence of 3% and 8% in the population. The aging demographic, increasing air pollution, and smoking patterns contribute to this condition which translates into a greater patient population seeking CHS therapy, which drives market growth.

Development of advanced therapeutics: Inhaled corticosteroids, leukotriene receptor antagonists, and neurokinin-1 receptor antagonists are among the most effective treatments for CHS. Current investigations into biologics and combination medicines offer the potential for market expansion.

Expanding healthcare infrastructure: The Mexican government invests in healthcare infrastructure, expanding insurance coverage, opening specific clinics, and implementing preventative health measures. Improved accessibility encourages treatment-seeking in patients, resulting in market expansion.

Market Restraints

Limited efficacy of existing treatments: Currently, there are no FDA-approved drugs specially designed for CHS. Existing treatment options include off-label drugs such as cough suppressants, inhaled corticosteroids, and proton pump inhibitors (PPIs) which have side effects and limited efficacy for long-term treatment, restricting market growth.

Fragmented healthcare system: Mexico's healthcare system is fragmented, with different providers and treatment regimes, posing challenges for CHS patients to access specialist care and limiting market growth. A shortage of pulmonologists and other professionals trained in diagnosing and managing CHS contributes to the problem, limiting access to efficient treatment.

Affordability challenges: Off-label medicines used to manage CHS are expensive, particularly for people with limited financial resources. Reimbursement for CHS treatment is limited by public and private coverage, restricting market access.

Healthcare Policies and Regulatory Landscape

In Mexico, the main regulatory body overseeing drugs, pharmaceuticals, and other health-related products is the Federal Commission for the Protection against Sanitary Risk (Comisión Federal para la Protección contra Riesgos Sanitarios or COFEPRIS). COFEPRIS operates under the Secretariat of Health and is responsible for ensuring the safety, efficacy, and quality of health products, as well as regulating their marketing, distribution, and sale.

The process of obtaining licensure for drugs and pharmaceuticals in Mexico involves submitting an application to COFEPRIS. If the product meets the required standards, COFEPRIS grants marketing authorization, allowing the product to be legally sold and distributed in the Mexican market.

For new entrants into Mexico's pharmaceutical sector, navigating the regulatory environment necessitates strict adherence to COFEPRIS requirements which is a complex and time-consuming process.

Competitive Landscape

Key Players

Pfizer
GlaxoSmithKline
Boehringer Ingelheim
AstraZeneca
Johnson & Johnson
Bayer
Novartis
Teva Pharmaceutical
Roche
Merck

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Mexico Cough Hypersensitivity Syndrome Therapeutics Market Segmentation

By Drug Class

Antitussive Agents
Corticosteroids
Short Acting Beta-2 Agonists
Anti-cholinergic
Antihistamines
Proton Pump Inhibitors
Others

By Route of Administration

Oral
Inhalation
Others

By End Users

Hospitals
Speciality Clinics
Homecare

By Distribution Channel

Hospital Pharmacies
Online Pharmacies
Retail Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.